Some studies mainly on adult patients suggested that CD56+, CD34+, or CD2+CD34+APL subgroup had a higher rate of relapse [23–25], however, this was not proved in our pediatric patients treated on SCCLG-APL protocol. This evidence concerns the gene CD2 and acute promyelocytic leukemia.